Table 1. Study characteristics.
| Name | Study Group | Single vs. multicenter/country | Study design | Randomized vs cohort | Publication | Year | NICM CRT-D | NICM CRT-P | Follow-up (months) | Outcomes | Adjustments made |
| ACEI: inhibitor indicates angiotensin-converting enzyme inhibitor; AF: atrial fibrillation; AM: all-cause mortality; COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronization therapy; CRT-D: CRT defibrillator; CRT-P: CRT pacemaker; CV: cardiovascular; CVD: cerebrovascular disease; HF: heart failure; UK: United Kingdom; US: United States; LVEF: left ventricular ejection fraction; MACE: major adverse; SCD: sudden cardiac death; NYHA: New York Heart Association Functional Classification for Heart Failure. | |||||||||||
| Kutyifa, et al. [9] |
N/A | Single center/Hungary | Retrospective | Cohort | Eur Hear J HF | 2014 | 209 | 458 | 28 | AM, LVEF improvement | Age and sex |
| Marijon et al [10] |
CeRtiTuDe trial | Multicenter/Europe | Prospective | Cohort | Eur Hear J | 2015 | 571 | 245 | 24 | AM | Propensity score |
| Witt, et al.[15] |
N/A | Single center/Denmark | Retrospective | Cohort | EP Europace | 2016 | 122 | 305 | 48 | AM | Apriori confounders |
| Kober, et al.[12] |
DANISH trial | Multicenter/Danish | RCT | RCT | N. Eng. J. Med | 2016 | 322 | 323 | 67.6 | AM; device infection | Time-to-event methods |
| Barra, et al.[11] |
French-UK-Sweden CRT Network | Multicenter/European | Retrospective | Cohort | JACC | 2017 | 1943 | 682 | 41.4 | AM | Propensity score |
| Drozd, et al.[16] |
N/A | Single center/UK | Prospective | Cohort | J Cardiova Med | 2017 | 25 | 240 | 35.2 | AM | Propensity score |
| Leyva, et al.[8] |
N/A | Multicenter/UK | Retrospective | Cohort | EP Europace | 2018 | 114 | 116 | 56.4 | AM, HF, MACE, cardiac mortality, SCD, VT/VF | Propensity score |
| Wang, et al.[17] |
N/A | Single center/US | Retrospective | Cohort | Indian Pacing | 2019 | 93 | 42 | 46 | AM | LVEF. ACE inhibitor use |
| Saba, et al. [18] |
N/A | Multicenter/US | Retrospective | Cohort | Heart Rhythm | 2019 | 4359 | 1236 | 60 | AM, medical costs | Cox proportional hazard |
| Gras, et al. [19] |
N/A | Multicenter/French | Retrospective | Cohort | Europace | 2020 | 9129 | 8176 | 30.4 | AM, cardiovascular and noncardiovascular death | Propensity score |
| Liang, et al. [20] |
N/A | Single center/China | Retrospective | Cohort | J CARDIOL | 2020 | 202 | 117 | 36 | AM | Propensity score |
| Doran, et al.[21] |
COMPANION trial | Multicenter/US | RCT | RCT | JACC HF | 2021 | 270 | 285 | 17.1 | AM, SCD, HF | Cox propensity hazards models |
| Schrage, et al. [22] | N/A | Multicenter/Sweden | Retrospective | Cohort | EP Europe | 2022 | 1108 | 880 | 28.2 | AM | Propensity score |
| Farouq, et al.[23] |
N/A | Multicenter/Sweden | Retrospective | Cohort | EP Europe | 2023 | 2693 | 2334 | 51.6 | AM | AF, Hypertension, LBBB, CKD, COPD, Malignancy, Age, Sex, CVD |